Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.68 |
| ▸ | CA1 | P00915 | 5/20 | 0.68 |
| ▸ | CA9 | Q16790 | 5/20 | 0.68 |
| ▸ | CA2 | P00918 | 4/20 | 0.68 |
| ▸ | CA7 | P43166 | 3/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.68 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 3/20 | 0.46 |
| ▸ | CA5A | P35218 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419325 | 1.00 | HCAR1 (1.00) | HCAR1CA12CA1CA9CA2 | |
| SCHEMBL336433 | 0.85 | HCAR1 (0.73) | HCAR1CA12CA1CA9CA2 | |
| SCHEMBL157714 | 0.85 | HCAR1 (0.73) | HCAR1CA12CA1CA9CA2 | |
| Hydrochloric Acid SCHEMBL2293148 | 0.82 | HCAR1 (0.70) | HCAR1CA12CA1CA9CA2 | |
| Hydrochloric Acid SCHEMBL6518491 | 0.82 | HCAR1 (0.70) | HCAR1CA12CA1CA9CA2 | |
| 3,5-Dihydroxybenzoic Acid SCHEMBL28106 | 0.82 | CA12 (1.00) | HCAR1CA12CA1CA9CA2 | |
| SCHEMBL139644 | 0.82 | CA12 (0.88) | HCAR1CA12CA1CA9CA2 | |
| 3,5-Dihydroxybenzoic Acid SCHEMBL618767 | 0.82 | CA12 (1.00) | HCAR1CA12CA1CA9CA2 | |
| 3,5-Dihydroxybenzoic Acid SCHEMBL1151737 | 0.79 | CA12 (0.94) | HCAR1CA12CA1CA9CA2 | |
| 3,5-Dihydroxybenzoic Acid SCHEMBL9693437 | 0.79 | CA12 (0.94) | HCAR1CA12CA1CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816940-A | Nicotine salts, co-crystals and salt co-crystal complexes | R.J.雷诺兹烟草公司 | 2021-12-21 | — | — | CN | claimed |
| CN-113754634-A | Nicotine salts, co-crystals and salt co-crystal complexes | R.J.雷诺兹烟草公司 | 2021-12-07 | — | — | CN | claimed |
| CN-110664793-A | Application of 3-hydroxy-5-substituted benzoic acid in preparing external medicine for treating eczema, dermatitis and psoriasis | 碧豫药业有限责任公司 | 2020-01-10 | — | — | CN | claimed |
| CN-110604702-A | Use of 3-hydroxy-5-substituted benzoic acids for the preparation of cosmetic or non-therapeutic skin treatment compositions | 碧豫药业有限责任公司 | 2019-12-24 | — | — | CN | claimed |
| US-20260107973-A1 | AEROSOL-MODIFYING ADDITIVE COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107972-A1 | AEROSOL GENERATING GEL MATERIAL COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107967-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107969-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12600710-B2 | Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260060287-A1 | AEROSOLIZABLE COMPOSITION INCLUDING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-5401604-A | Reaction product of polyepoxide, aromatic acid with phenolic hydroxy group, aromatic acid, quinone diazide with sulfonyl group, photoresists | NIPPON PAINT CO., LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0354018-B1 | An electrodeposition coating composition and image-forming method using the same | NIPPON PAINT CO LTD (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0302941-B1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION AND PROCESS FOR ITS PRODUCTION | NIPPON PAINT CO LTD (JP) | 1993-12-29 | — | — | EP | disclosed |
| US-5166036-A | Photoresists for positives for printed circuits | NIPPON PAINT CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5055374-A | Positive working resist | NIPPON PAINT CO., LTD. (JP) | 1991-10-08 | — | — | US | disclosed |
| US-4999274-A | Obtained by Reacting a Polyepoxide Compound, an Aromatic or Heterocyclic Carboxylic Acid Bearing a Phenolic Hydroxyl Group and a 1,2-Quinondiazido Sulfonyl Halide; Lithographic Plates, Photoresists | NIPPON PAINT CO., LTD. (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0354018-A2 | An electrodeposition coating composition and image-forming method using the same | NIPPON PAINT CO., LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| EP-0302941-A1 | POSITIVE PHOTOSENSITIVE RESIN COMPOSITION AND PROCESS FOR ITS PRODUCTION | NIPPON PAINT CO., LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, CHRM1 | HCAR1 3353/4885CA12 2583/4885CA1 2910/4885 |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | ALK, EXOSC4, EXOSC9 | HCAR1 4006/4885CA12 4013/4885CA1 4122/4885 |
| US-20260107967-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EXOSC4, CHRM3 | HCAR1 3612/4885CA12 3474/4885CA1 4305/4885 |
| US-12600710-B2 | Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors | BCL9, BCL9L, BCL3 | HCAR1 1993/4885CA12 632/4885CA1 758/4885 |
| US-20260107969-A1 | AEROSOL GENERATING MATERIAL COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | CHRM1, CHRM3, ATRIP | HCAR1 2895/4885CA12 3691/4885CA1 4118/4885 |
| US-20260060287-A1 | AEROSOLIZABLE COMPOSITION INCLUDING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | CHRM3, CHRM1, ADRA1D | HCAR1 3930/4885CA12 3881/4885CA1 4162/4885 |
| US-20260107973-A1 | AEROSOL-MODIFYING ADDITIVE COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | CHRM3, CHRM1, CHRM2 | HCAR1 3783/4885CA12 3077/4885CA1 4011/4885 |
| US-20260107972-A1 | AEROSOL GENERATING GEL MATERIAL COMPRISING A SUBSTITUTED 3-(1 METHYLPYRROLIDIN-2-YL)PYRIDINE | ACTN1, ARPC3, ARPC4 | HCAR1 4504/4885CA12 3688/4885CA1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.